Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03128996 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Study acronym: FAM BMT
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 1 of 4 sitesv11
  2. Primary completion date: Apr 2026 to Apr 2028
    • Study sites: 3 to 4
    • Study completion date: Apr 2031 to Apr 2033
    v10
  3. Primary completion date: Apr 2024 to Apr 2026
    • Study completion date: Apr 2026 to Apr 2031
    v9
  4. Study sites: 2 to 3v8
  5. Re-verified, no change to tracked fieldsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 1 to 2
    • Eligibility criteria expanded, about 76 words
    v6
  2. Primary completion date: Apr 2022 to Apr 2024
    • Study completion date: Apr 2024 to Apr 2026
    v5
  3. 2 versions Re-verified since May 4, 2018, no change to tracked fieldsv3-v4
  4. Interventions: Transplant conditioning and GVHD prophylaxis (Drug) to GVHD prophylaxis regimen (Drug), RIC regimen (Drug)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
Trial Details
NCT Number NCT03128996
Lead Sponsor Washington University School of Medicine
Conditions
(from sponsor)		 Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Related terms Anemia, Sickle Cell, Bone Marrow Failure Disorders, Hemoglobinopathies, Immune System Diseases, Metabolic Diseases
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov